Seizing the Best Opportunities with a dedicated M&A and In-Licensing team
The M&A and In-Licensing department at LXO Group plays a pivotal role in the company’s external growth. Working closely with our investment fund, our mission is to identify, assess, and secure the best growth opportunities—whether through acquisitions or licensing agreements—to enhance our portfolio with high-potential medical and commercial assets aligned with our Life Cycle Management capabilities.
Thanks to a strong network of industry players (pharmaceutical companies, investment banks, specialised advisory firms, and investors), we maintain a steady and high-quality deal flow across Europe and internationally.
Our approach is built on:
- A fast and rigorous evaluation of opportunities, using a proven methodology to ensure swift and strategic positioning.
- An efficient due diligence process, conducted alongside recognised industry experts.
- An agile and structured execution, ensuring secure transactions and smooth integration of assets or products.
By working in close coordination with our regulatory, market access, pharmaceutical operations, and commercial teams, we ensure that each opportunity fits seamlessly into our strategy and meets market expectations.
Our ambition : to turn every transaction into a sustainable growth driver and a source of long-term value for the group.
M&A
Our M&A strategy is focused on strengthening our portfolio of differentiated and specialised medicines. We target assets or companies that can enrich our pipeline or accelerate our entry into new markets.
Each opportunity is assessed against strict criteria: strategic relevance, commercial potential, complementarity, team quality, and regulatory environment. Thanks to our agile organisation and rigorous methodology, we can:
- Quickly identify relevant targets,
- Conduct robust analyses for rapid positioning,
- Engage in and execute transactions seamlessly and securely.
We place particular emphasis on preserving the value of acquired brands and ensuring their smooth integration, guaranteeing post-acquisition continuity and success.
In-Licencing
LXO Group collaborates with innovative companies worldwide to secure commercialisation rights for promising products, particularly in the cardiovascular and CNS therapeutic areas.
- We seek products that are:Medically high-value,
- Differentiated in terms of formulation, clinical profile, or regulatory positioning,
- Well-suited to the needs of key target markets (EU5).
Our team ensures a seamless relationship with partners, from the initial contact through to agreement signing, with a swift evaluation of potential and integration into our strategic roadmap.
Our in-licensing agreements enable us to accelerate access to innovative treatments while optimising our time-to-market.
Would you like to learn more about the LXO group?
Whether you are looking for high-quality medications or want to join our collective journey, you are in the right place.